Study of ongoing registered clinical trials on COVID-19
a narrative review
Keywords:
SARS virus, Therapeutics, Vaccines, RecordsAbstract
BACKGROUND: The dangerous SARS-CoV-2 virus first emerged in China in December 2019 and has rapidly spread worldwide. Currently, it has affected more than 2,850,000 people. No vaccine or drug is available yet, and therefore researchers and scientists are striving to identify potential drugs or vaccines for combating this virus. We were unable to find any review of the literature or analysis on ongoing registered clinical trials that reported diagnostic tests, therapeutics, vaccines and devices for COVID-19 along with estimated enrollment, participants’ ages, study type, start and completion date, status, treatment/intervention and country. OBJECTIVE: To review ongoing trials relating to COVID-19. METHODS: A systematic search for clinical trials was conducted in the ClinicalTrials.gov database up to April 12, 2020. A total of 339 trials relating to COVID-19 were analyzed and key information on each trial was recorded. RESULTS: Most of the trials were being conducted in the United States and completion of most of them was expected by May 2020. They were mostly on drugs and treatment, while a minority were on diagnostic tests. The analysis showed that hydroxychloroquine was investigated in most of the trials. The trials identified were categorized into five classes: a) diagnostic tests; b) therapeutics; c) biologics and vaccines; d) devices and products; and e) others. CONCLUSION: The trials identified have potential against COVID-19 that can be applied in treatment processes after the necessary investigations and experiments. Additionally, the items identified were organized in a proper way, which can assist in current research activities.
Downloads
References
World Health Organization. Novel coronavirus (2019-nCoV). Situation report - 15. Available from: Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200204-sitrep-15-ncov.pdf?sfvrsn=88fe8ad6_4 Accessed in 2020 (May 4).
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. PMID: 32007143; doi: 10.1016/S0140-6736(20)30211-7.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. PMID: 31986264; doi: 10.1016/S0140-6736(20)30183-5.
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. PMID: 31978945; doi: 10.1056/NEJMoa2001017.
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-20. PMID: 23075143; doi: 10.1056/NEJMoa1211721.
Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353-8. PMID: 14585636; doi: 10.1016/s0140-6736(03)14630-2.
Chen J. Pathogenicity and transmissibility of 2019-nCoV − a quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69-71. PMID: 32032682; doi: 10.1016/j.micinf.2020.01.004.
Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689-97. PMID: 32014114; doi: 10.1016/S0140-6736(20)30260-9.
Pang J, Wang MX, Ang IYH, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020;9(3):623. PMID: 32110875; doi: 10.3390/jcm9030623.
Hançer AT, Yilmaz P, Yilmaz M. New Coronavirus (2019-nCoV/COVID-19) and Vitamin C. Turkiye Klinikleri J Med Sci. 2020;40(2):260-4. doi: 10.5336/medsci.2020-76024.
Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40. PMID: 32256547; doi: 10.26633/RPSP.2020.40.
Tu YF, Chien CS, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21(7):2657. PMID: 32290293; doi: 10.3390/ijms21072657.
Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;ciaa310. PMID: 32198501; doi: 10.1093/cid/ciaa310.
Information on Clinical Trials and Human Research Studies. Available from: Available from: https://clinicaltrials.gov Accessed in 2020 (May 4).
Xinhua. Antimalarial drug confirmed effective on COVID-19. Available from: Available from: http://www.xinhuanet.com/english/2020-02/17/c_138792545.htm Accessed in 2020 (May 4).
Servick K. Antimalarials widely used against COVID-19 heighten risk of cardiac arrest. How can doctors minimize the danger? Available from: Available from: https://www.sciencemag.org/news/2020/04/antimalarials-widely-used-against-covid-19-heighten-risk-cardiac-arrest-how-can-doctors Accessed in 2020 (May 4).
BGI develops real-time fluorescent RT-PCR kit for detecting the 2019 novel coronavirus. Available from: Available from: https://www.bgi.com/global/company/news/bgi-develops-real-time-dna-based-kit-for-detecting-the-2019-novel-coronavirus/ Accessed in 2020 (May 5).
Study of safety and immunogenicity of BVRS-GamVac-Combi. Available from: Available from: https://clinicaltrials.gov/show/NCT04128059 Accessed in 2020 (May 5).
Randomized, double-blind, placebo-controlled, phase Ib study to assess the safety and immunogenicity of MVA-MERS-S_DF-1. Available from: Available from: https://clinicaltrials.gov/show/NCT04119440 Accessed in 2020 (May 5).
CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019. Available from: Available from: https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/ Accessed in 2020 (May 5).
Weiner DE, Sarnak MJ. Cardiovascular disease in patients with chronic kidney disease. In: Himmelfarb J, Sayegh MH, editors. Chronic Kidney Disease, Dialysis, and Transplantation. Philadelphia: Saunders; 2010. p. 128-44.
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. PMID: 32020029; doi: 10.1038/s41422-020-0282-0.
Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PloS One. 2009;4(11):e7838. PMID: 19893749; doi: 10.1371/journal.pone.0007838.
Uyeki TM. Oseltamivir treatment of influenza in children. Clin Infect Dis. 2018;66(10):1501-3. PMID: 29315362; doi: 10.1093/cid/cix1150.
Rabby MII. Current drugs with potential for treatment of COVID-19: a literature review. J Pharm Pharm Sci. 2020;23(1):58-64. PMID: 32251618; doi: 10.18433/jpps31002.
Pharmacoeconomic Review Report: Sarilumab (Kevzara). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017. PMID: 30489710; NBK534401.
Wang Y, Jiang Y, Zhao X, Weiqing HE, inventors; Shenyang Fuyang Pharmaceutical Technology Co Ltd, assignee. Use of carrimycin in mycobacterium tuberculosis infection resistance. United States patent application US 16/067,327. 2019.
Fredlund P, Hillson J, Gray T, et al. Peginterferon Lambda-1a (Lambda) is Associated With Less Autoimmune Thyroid Disease and Serious Autoimmune Disease Than Peginterferon Alfa-2a (Alfa) When Used in Combination With Ribavirin (RBV) for the Treatment of Chronic Hepatitis C Virus Infection: 781. Hepatology. 2012;56:571A. Available from: Available from: https://insights.ovid.com/crossref?an=01515467-201210001-00786&clickthrough=y Accessed in 2020 (May 6).
Tang TX. Application of Xiyanping in treatment of infantile rotavirus diarrhea. Journal of Hainan Medical University 2016;22(13):113-5. Available from: Available from: http://www.hnykdxxb.com/PDF/201613/30.pdf Accessed in 2020 (May 5).
Carr EA. Systemic inflammatory response syndrome. In: Robinson’s Current Therapy in Equine Medicine. Philadelphia: Saunders ; 2015. p. 741-5.
Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;10.1938/d41573-020-00073-5. PMID: 32273591; doi: 10.1038/d41573-020-00073-5.
Weiner P, Magadle R, Beckerman M, Weiner M, Berar-Yanay N. Specific expiratory muscle training in COPD. Chest. 2003;124(2):468-73. PMID: 12907530; doi: 10.1378/chest.124.2.468.
Monnet X, Teboul JL. Transpulmonary thermodilution: advantages and limits. Crit Care. 2017;21(1):147. PMID: 28625165; doi: 10.1186/s13054-017-1739-5.
Smart Patients. Therapeutic Vaccination in Treated HIV Disease. Available from: https://www.smartpatients.com/trials/NCT03606213 Accessed in 2020 (May 5).
